MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Home・Aandelen Lijst・Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

8.79 -1.57

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

8.79

Max

8.88

Belangrijke statistieken
By Trading Economics
Inkomsten	22M 23M
Verkoop	2.6M 62M
K/W Sectorgemiddelde	27.667 39.564
Winstmarge	37.371
Werknemers	130
EBITDA	15M 22M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+10.8% upside

Dividenden
By Dow Jones
Volgende Winsten	31 jul 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-119M 1B
Vorige openingsprijs	10.36
Vorige sluitingsprijs	8.79

Nieuwssentiment

By Acuity

50%

131 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

8.1 / 8.21 Steun & Weerstand

Aurinia Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 jul 2025, 22:19 UTC

Acquisities, Fusies, Overnames

FCC Approves U.S. Cellular Sale to T-Mobile

11 jul 2025, 17:28 UTC

Belangrijke Marktbewegers

SharpLink Gaming Gains on Ethereum Purchase

11 jul 2025, 16:57 UTC

Winsten

BASF Cuts Outlook on Global Economy Uncertainty

13 jul 2025, 23:54 UTC

Marktinformatie

Oil Edges Higher Amid Supply Disruption Worries -- Market Talk

13 jul 2025, 23:49 UTC

Marktinformatie

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

13 jul 2025, 23:49 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 jul 2025, 23:40 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

13 jul 2025, 23:40 UTC

Marktinformatie

Gold Advances Amid Rising Trade Tensions -- Market Talk

13 jul 2025, 23:39 UTC

Marktinformatie

China's Growth Momentum Likely Slowed in 2Q -- Market Talk

13 jul 2025, 23:16 UTC

Winsten

China Shenhua Energy 1H 2024 Net Was CNY32.8B>1088.HK

13 jul 2025, 23:16 UTC

Winsten

China Shenhua Energy: Drop in Coal Prices Weighed on Results >1088.HK

13 jul 2025, 23:16 UTC

Winsten

China Shenhua Energy Sees 1H Net CNY25.6B-Net CNY27.6B >1088.HK

13 jul 2025, 23:13 UTC

Marktinformatie

Global Equities Roundup: Market Talk

13 jul 2025, 23:13 UTC

Marktinformatie

Ryman Healthcare Could Be Turning a Corner -- Market Talk

13 jul 2025, 11:00 UTC

Acquisities, Fusies, Overnames

The Private-Equity Maneuver Allowing More Investors to Cash Out -- WSJ

12 jul 2025, 02:24 UTC

Acquisities, Fusies, Overnames

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 jul 2025, 02:05 UTC

Acquisities, Fusies, Overnames

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 jul 2025, 02:05 UTC

Acquisities, Fusies, Overnames

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 jul 2025, 02:05 UTC

Acquisities, Fusies, Overnames

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 jul 2025, 21:45 UTC

Marktinformatie

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 jul 2025, 19:46 UTC

Acquisities, Fusies, Overnames

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 jul 2025, 19:45 UTC

Marktinformatie

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 jul 2025, 19:05 UTC

Marktinformatie

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 jul 2025, 18:18 UTC

Marktinformatie

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 jul 2025, 17:35 UTC

Marktinformatie

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 jul 2025, 17:26 UTC

Marktinformatie

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 jul 2025, 16:53 UTC

Marktinformatie

Crude Futures Add to Early Gains -- Market Talk

11 jul 2025, 16:42 UTC

Winsten

BASF Cuts Outlook on Global Economic Uncertainty

11 jul 2025, 16:08 UTC

Marktinformatie

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 jul 2025, 16:05 UTC

Winsten

BASF Will Publish Half-Year Results on July 30

Peer Vergelijking

Prijswijziging

Aurinia Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

10.8% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9.75 USD 10.8%

Hoogste 11 USD

Laagste 8 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Aurinia Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Aurinia Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

8.1 / 8.21Steun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bullish event.

Sentiment

By Acuity

131 / 376 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.